HCV/Hepatitis C Drugs in Pipeline Forecast

NEW YORK, Sept. 8, 2015/PRNewswire/ - Market for Hepatitis C medications has developed with a remarkable rate of more than US$ 13 Billion, in the year 2014 contrasted with 2013. In the most recent two years two or three new medications have been presented in the business which has turned into a gigantic achievement and they have caught greatest piece of the overall industry of the Hepatitis C market. Gilead as of now overwhelms the multi-billion dollar Hepatitis C market, however AbbVie has been attempting to build its piece of the overall industry since U.S. controllers endorsed the showcasing of its Viekira Pak. Drug creators are now concentrating on presenting new medications in the business sector as a few medications are remaining in the pipeline. Hepatitis C Drugs is expected to be a blushing business for future period.

This is third version report on Hepatitis C Drugs Industry by Renub Research. Report titled "Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global" gives a far reaching appraisal of the quick developing, high-development of Hepatitis area. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.

1. Hepatitis C Drugs Market & Forecast (Chapter 2)

2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)

3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4)

4. Hepatitis C Deals & Acquisitions (Chapter 5)

5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6)

Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)

1. Pegasys

2. Pegintron

3. Incivek

4. Victrelis

5. Olysio

6. Sovaldi/Harvoni

7. HCV Franchise

8. Viekira Pak

Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)

1. Drug A (Merck & Co. Inc.)

2. Drug B (Merck & Co. Inc.)

3. Drug C (Bristol-Myers Squibb)

Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5)

1. AbbVie

2. Bristol-Myers Squibb (BMS)

3. Gilead Sciences

4. Merck & Co. Inc.

5. Tibotec/Janssen Therapeutics

Information Sources

This report is constructed utilizing information and data sourced from restrictive databases, essential and auxiliary examination and in-house investigation by Renub Research group of industry specialists.

Essential sources incorporate industry overviews and phone interviews with industry specialists.

Auxiliary sources data and information has been gathered from different printable and non-printable sources like internet searchers, News sites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade affiliations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Perused the full report: http://www.reportlinker.com/p03207032-synopsis/view-r